Tests a UVB laser for vitiligo, psoriasis, alopecia areata and atopic dermatitis
Tests a UVB laser in adults with vitiligo, psoriasis, alopecia areata or atopic dermatitis.
Plain-language title generated from the registry record
Registry title: PALLAS Laser for Skin Diseases
Key facts
- Where
- Szeged, HungarySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07250997, who can take part
Where in Hungary
- University of Szeged, Albert Szent-Györgyi Clinical Centre, Department of Dermatology and AllergologySzeged, HungaryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Szeged University
- Trial code
- NCT07250997
- Record updated
- 6 February 2026
- Original description
The primary objective of this study is to get clinical experiences with the PALLAS laser in the treatment of skin conditions that respond well to UV light (vitiligo, psoriasis, alopecia areata, atopic dermatitis).Read full original descriptionShow less
Study of the Effectiveness of the PALLAS Laser in the Treatment of Skin Diseases That Respond Well to UV Light
The primary objective of this study is to get clinical experiences with the PALLAS laser in the treatment of skin conditions that respond well to UV light (vitiligo, psoriasis, alopecia areata, atopic dermatitis).
The secondary objective is to assess how user-friendly is the Pallas laser in the treatment of skin diseases.
The patient in the trial will receive UVB laser treatment (2 treatments per week for up to 3 months). The treatments will be carried out by the doctors participating in the trial.
The treatment takes approximately 10 minutes per session, and can last up to 3 months per patient.
Photographic documentation of the lesions to be treated and the lesions treated is taken at the start of the examination and then once a month.
At the end of the study, the patient rates the treatment and improvement on a Patient Satisfaction Scale.
Inclusion: The subject understands the information provided, gives informed consent to participate in the study and is deemed by the investigator to be able to participate,; a skin condition that is expected to respond well to targeted UVB treatment,; a signed consent form.
Exclusion: epilepsy,; fever, infectious diseases,; Patient under 18 years of age,; pregnancy; the patient is within one month or currently enrolled in another clinical trial.